Literature DB >> 3278942

5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis.

W L Biddle1, N J Greenberger, J T Swan, M S McPhee, P B Miner.   

Abstract

The efficacy of 5-aminosalicylic acid enemas in maintaining remission in left-sided ulcerative colitis was studied. Twenty-five patients in remission for at least 2 mo were randomized to receive either 1-g 5-aminosalicylic acid or placebo enemas daily and were followed up for 1 yr. Eleven of 13 patients randomized to placebo relapsed after a mean of 16 wk. Nine of 12 patients randomized to 5-aminosalicylic acid remained in remission for 1 yr, 2 others in remission withdrew by request, and 1 relapsed at 10 wk. The difference between relapse rate on 1-g 5-aminosalicylic acid versus placebo was significant (p less than 0.005). Seven patients entered the blinded trial a second time. Three of 4 patients randomized to 5-aminosalicylic acid remained in remission and 1 relapsed. Three randomized to placebo relapsed at a mean of 14 wk. One-gram 5-aminosalicylic acid enemas are safe and effective in maintaining remission in patients with left-sided ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278942     DOI: 10.1016/0016-5085(88)90569-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

2.  Meta-analysis of the placebo response in ulcerative colitis.

Authors:  Sagar Garud; Alphonso Brown; Adam Cheifetz; Emily B Levitan; Ciaran P Kelly
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 3.  AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Siddharth Singh; Joseph D Feuerstein; David G Binion; William J Tremaine
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

Review 4.  AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Cynthia W Ko; Siddharth Singh; Joseph D Feuerstein; Corinna Falck-Ytter; Yngve Falck-Ytter; Raymond K Cross
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

Review 5.  Hypersensitivity to 5-ASA suppositories.

Authors:  M L Borum; A Ginsberg
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

6.  Enemas for IBD maintenance therapy.

Authors:  L R Sutherland; F Martin
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

7.  Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

Authors:  Javier P Gisbert; Fernando Gomollón; José Maté; José María Pajares
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

8.  Failure of 5-aminosalicylic acid enemas to improve chronic radiation proctitis.

Authors:  C A Baum; W L Biddle; P B Miner
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

Review 9.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

10.  Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.

Authors:  P Miner; S Hanauer; M Robinson; J Schwartz; S Arora
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.